High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Daniel B ReevesBryan T MayerAllan C deCampYunda HuangBo ZhangLindsay N CarppCraig A MagaretMichal JuraskaPeter B GilbertDavid C MontefioriKatharine J BarErwing Fabian Cardozo OjedaJoshua T SchifferRaabya RossenkhanPaul T EdlefsenLynn MorrisNonhlanhla N MkhizeCarolyn WilliamsonJames I MullinsKelly E SeatonGeorgia D TomarasPhilip AndrewNyaradzo MgodiJulie E LedgerwoodMyron S CohenLawrence CoreyLogashvari NaidooCatherine OrrellPaul A GoepfertMartín Casapía-MoralesMagdalena E SobieszczykShelly T KarunaSrilatha EdupugantiPublished in: Nature communications (2023)
The Antibody Mediated Prevention (AMP) trials (NCT02716675 and NCT02568215) demonstrated that passive administration of the broadly neutralizing monoclonal antibody VRC01 could prevent some HIV-1 acquisition events. Here, we use mathematical modeling in a post hoc analysis to demonstrate that VRC01 influenced viral loads in AMP participants who acquired HIV. Instantaneous inhibitory potential (IIP), which integrates VRC01 serum concentration and VRC01 sensitivity of acquired viruses in terms of both IC50 and IC80, follows a dose-response relationship with first positive viral load (p = 0.03), which is particularly strong above a threshold of IIP = 1.6 (r = -0.6, p = 2e-4). Mathematical modeling reveals that VRC01 activity predicted from in vitro IC80s and serum VRC01 concentrations overestimates in vivo neutralization by 600-fold (95% CI: 300-1200). The trained model projects that even if future therapeutic HIV trials of combination monoclonal antibodies do not always prevent acquisition, reductions in viremia and reservoir size could be expected.